Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01726582 · ClinicalTrials.gov registry record · Phase 2
Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine")
A Phase 2 study, sponsored by Medical College of Wisconsin.
- Completed
- Registry status
- Phase 2
- Development phase
- 229
- Enrollment target
NCT01726582: Completed Phase 2 study, sponsored by Medical College of Wisconsin.
NCT01726582 is a Phase 2 study that has completed, run by Medical College of Wisconsin. The registered enrollment target is 229 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (72% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01726582, a Phase 2 study, has completed, sponsored by Medical College of Wisconsin.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 229 participants
- Enrollment target
Study Summary
In this clinical trial, if the doctor knows or suspects that a growth in the pancreas is cancer (adenocarcinoma), then a sample of the growth is tested (the test is called molecular profiling). The results of the test are used by the doctor to recommend therapy (chemotherapy and radiation therapy) that the patient will receive before having surgery to remove the adenocarcinoma. When the patient goes to surgery, the adenocarcinoma that is removed is tested again. The results of that test are used to guide the choice of therapy after surgery. The chemotherapy drugs and the radiation therapy used in this clinical trial are already approved for treatment of pancreas cancer. This trial is intended to establish which treatment is best for a specific patient, based on test results from that patient's actual adenocarcinoma. In the past, the decision as to which treatment the patient will receive was not based on testing of the actual adenocarcinoma. See treatment pathways at http://www.mcw.edu/surgery/patientinfo/Pancreatic-Cancer-Trial.htm. Hypothesis: Resectability rate, overall survival rate and progression-free survival in subjects with adenocarcinoma of the pancreas will be superior for who receive targeted "personalized" therapy.
Primary Outcome
This outcome measure is the number of subjects completing therapy up to and including surgical resection. In this context, surgical excision of residual tumor is an option in the progression of usual care. Surgery was contraindicated for some participants. This measure is the number of subject who were eligible for and completed the surgical procedure.
Interventions
- DRUG Milestone 1: Targeted chemotherapy prior to surgery
- RADIATION Milestone 2: Chemoradiotherapy (cXRT)
- DRUG Milestone 3: Targeted chemotherapy prior to surgery
- RADIATION Milestone 3: Chemoradiotherapy (cXRT)
- DRUG Milestone 4: standard FOLFIRINOX chemotherapy prior to surgery
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 229 participants |
| Start Date | 2011-11 |
| Est. Completion | 2022-04-11 |
| Phase | Phase 2 |
What the finished NCT01726582 record still lists
NCT01726582 is an interventional study that assigns participants to a tested intervention. The registered 229 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (72% higher).
The record links to 0 conditions, and to 5 interventions - of which Milestone 1: Targeted chemotherapy prior to surgery is the first listed.
NCT01726582 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01726582 about?
NCT01726582 is a clinical study titled "Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine")". In this clinical trial, if the doctor knows or suspects that a growth in the pancreas is cancer (adenocarcinoma), then a sample of the growth is tested (the test is called molecular profiling). The results of the test are used by the doctor to recommend therapy (chemotherapy and radiation therapy) t...
What is the current status of trial NCT01726582?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 229 participants. The study started on 2011-11. Estimated completion is 2022-04-11.
What interventions are being tested in trial NCT01726582?
The interventions under investigation include: Milestone 1: Targeted chemotherapy prior to surgery (DRUG), Milestone 2: Chemoradiotherapy (cXRT) (RADIATION), Milestone 3: Targeted chemotherapy prior to surgery (DRUG), Milestone 3: Chemoradiotherapy (cXRT) (RADIATION), Milestone 4: standard FOLFIRINOX chemotherapy prior to surgery (DRUG).
Who is sponsoring clinical trial NCT01726582?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01726582's enrollment target sits among peer trials
229 264th of 2000 higher than 1,737 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02710253 · 230 participants · Phase 2
Salvage Radiation Therapy in Treating Patients With Metastatic Cancer That Has Progressed After Systemic Immunotherapy
- NCT02777879 · 230 participants
Lung Microbiome and Inflammation in Early COPD
- NCT03824483 · 230 participants · Phase 2
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
- NCT03833622 · 230 participants · NA
Shared Decision Making to Improve Goals of Care in the ED
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia